A patient asked me last week if I could write him a prescription for MOTS-c. He'd read about it, tried ordering some online once, and wanted to do it the right way this time — a real provider, a real pharmacy. I had to tell him no. Not because I didn't want to help — because as the rules stand today, I can't do it legally. Neither can any other licensed provider going through a real pharmacy.

That answer catches people off guard. Peptides are everywhere — in gyms, on forums, in the DMs of every fitness influencer with a discount code. So how can something this common be off-limits? The honest version is that most of the peptides people are talking about live in a legal gray zone, and the rules governing them are moving faster right now than they have in years. There's an FDA meeting later this month that could shift what's available. Here's where things actually stand.

How compounded peptides are supposed to work

Start with a fact that surprises most people: almost none of the peptides in the longevity world are FDA-approved drugs. There's no brand-name BPC-157 sitting behind a pharmacy counter. Instead, these get made by compounding pharmacies — the same kind of pharmacy that makes a custom dose or a dye-free version of a medication you already know.

Compounding is legal and genuinely useful, but it runs on a specific rulebook. Under a piece of federal law called Section 503A, a pharmacy can only compound from raw ingredients — "bulk substances" — that the FDA has cleared for that use. Think of it as an approved-ingredients list. If a substance is on the list, pharmacies can work with it. If it isn't, they can't, at least not without inviting an enforcement problem.

What happened in 2023

In late 2023, the FDA worked through a large batch of nominated peptides and placed around nineteen of them into a bucket it calls Category 2 — substances it considered to carry enough open safety questions that they shouldn't be compounded at all. That list read like the menu at any peptide clinic: BPC-157, TB-500, CJC-1295, ipamorelin, epitalon, MOTS-c, semax, selank, melanotan II, and more.

The reasoning wasn't that these compounds had been proven to harm people. It was mostly that the information submitted to support them was thin — not enough solid data on purity, dosing, and safety to green-light widespread compounding. Fair or not, that single designation is what pushed a lot of peptide use underground, into the "research chemical" market I'll come back to.

What's changed since

This is the part everyone's been fired up about online.

Starting in 2024, some of those Category 2 labels began to come off. In September 2024, five peptides — including CJC-1295, ipamorelin, and thymosin alpha-1 — were pulled back out after the original nominations were withdrawn. Then in April 2026, the FDA removed about a dozen more, BPC-157 among them. The full reasoning behind these removals hasn't been spelled out publicly, and I'd take the confident narratives floating around online with a grain of salt.

But here's the part that gets lost in the hype. Coming off the Category 2 "do not compound" list is not the same as being cleared to compound. It only means the explicit prohibition is gone. To actually be legal to prescribe and make, a peptide still has to earn a spot on that approved-ingredients list. Most of these are stuck in between right now: no longer banned, not yet allowed.

Coming off the "do not compound" list isn't the same as being cleared to compound. It means the ban is gone — not that the door is open.

The FDA meeting later this month

On July 23 and 24, the FDA's compounding advisory committee is scheduled to meet and evaluate seven peptides for a place on the approved list:

If the committee votes in favor and the FDA follows its recommendation, these could become legally compoundable — meaning a provider like me could prescribe them and a licensed pharmacy could make them, on the level. For several of these, that would be the first real path to legal access in years.

I want to sit on the word "if" for a second. An advisory committee can recommend against a substance, and the FDA isn't bound by the committee either way. Final guidance also tends to take months to follow a meeting. So this is not "peptides are back on July 24." It's "the most credible route to legal access in years opens up, and we'll know far more once that meeting happens."

What's still firmly off the table

One category is moving in the opposite direction, and you should know about it.

Semaglutide and tirzepatide — the active ingredients in the well-known weight and metabolic medications — came off the FDA's drug shortage list in 2024 and 2025. Once a drug is no longer in shortage, the window for pharmacies to compound it in bulk closes. Those deadlines have passed, and in April 2026 the FDA proposed shutting that door permanently. If you've been getting inexpensive compounded semaglutide, that supply is drying up, and the legitimate route now runs through the brand-name products.

What we can offer now — and how we're watching this

So what does an honest peptide practice look like in the middle of all this?

Today, the growth-hormone-releasing peptides with the firmest legal footing are the ones we can work with through licensed compounding pharmacies — sermorelin is the clearest example. Tesamorelin exists as an FDA-approved medication for a specific, narrow indication. Beyond that, for the compounds still stuck in limbo, the responsible answer is the same one I gave that patient: not yet.

Here's what we're doing in the meantime:

If a peptide you're interested in becomes legally available, we'll offer it the right way — real prescription, real pharmacy, real oversight — or we won't offer it at all. That's the entire reason to do this through a provider instead of a website.

And if a podcast host told you something about a peptide that sounds a little too good to be true, I'm glad to talk through what the actual evidence, and the actual law, say about it.